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RESEARCH ARTICLE
Longitudinal Development of Peripapillary
Hyper-Reflective Ovoid Masslike
Structures Suggests a Novel Pathological
Pathway in Multiple Sclerosis
Axel Petzold, MD, PhD ,1,2,3,4 Danko Coric, MD,1,5 Lisanne J. Balk, PhD,1,5
Steffen Hamann, MD, PhD,6 Bernard M. J. Uitdehaag, MD, PhD,5
Alastair K. Denniston, MD,4,7,8 Pearse A. Keane, MD,6 and David P. Crabb, PhD 9
Objective: Peripapillary hyper-reflective ovoid masslike structures (PHOMS) are a new spectral domain optical coher-
ence tomography (OCT) finding.
Methods: This prospective, longitudinal study included patients (n = 212) with multiple sclerosis (MS; n = 418 eyes), 59 healthy
controls (HCs; n = 117 eyes), and 267 non-MS disease controls (534 eyes). OCT and diffusion tensor imaging were used.
Results: There were no PHOMS in HC eyes (0/117, 0%). The prevalence of PHOMS was significantly higher in patients
with MS (34/212, p = 0.001) and MS eyes (45/418, p = 0.0002) when compared to HCs (0/59, 0/117). The inter-rater
agreement for PHOMS was 97.9% (kappa = 0.951). PHOMS were present in 16% of patients with relapsing–remitting,
16% of patients with progressive, and 12% of patients with secondary progressive disease course (2% of eyes). There
was no relationship of PHOMS with age, disease duration, disease course, disability, or disease-modifying treatments.
The fractional anisotropy of the optic radiations was lower in patients without PHOMS (0.814) when compared to
patients with PHOMS (0.845, p = 0.03). The majority of PHOMS remained stable, but increase in size and de novo
development of PHOMS were also observed. In non-MS disease controls, PHOMS were observed in intracranial hyper-
tension (62%), optic disc drusen (47%), anomalous optic discs (44%), isolated optic neuritis (19%), and optic atro-
phy (12%).
Interpretation: These data suggest that PHOMS are a novel finding in MS pathology. Future research is needed to
determine whether development of PHOMS in MS is due to intermittently raised intracranial pressure or an otherwise
impaired “glymphatic” outflow from eye to brain.
ANN NEUROL 2020;00:1–11
Introduction
The optic disc has been of interest in multiple sclerosis
(MS) since the original description of structural changes
observed following optic neuritis.1,2 Early postmortem his-
tological observations of the optic disc were that “nerve-
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fibers showed numerous spindle-shaped swellings […].
Adhering to the nerve-fibers were very numerous ovoid
flattened nuclei […].”3 This was interpreted to represent
“nutritive hyperplasia” supposedly of “increased activity of
the protoplasm.”3
Longitudinal study of these ovoid structures has
been challenging, because they are buried below the nerve
fiber layer and due to the need for histology. With the
introduction of retinal optical coherence tomography
(OCT), it has become possible to study retinal structures
in much more detail than previously possible.4 These
ovoid structures have recently been termed peripapillary
hyper-reflective ovoid masslike structures (PHOMS) by an
international consensus panel.5 Current evidence suggests
that these PHOMS originate from axoplasmic stasis or
congestion in the prelaminar optic nerve head.6 The
occurrence of PHOMS in MS has not yet been studied,
with studies almost exclusively focusing on quantitative
assessment of the peripapillary retinal nerve fiber layer
(pRNFL) from an OCT ring scan rather than qualitative
assessment of optic disc volume scans.4,7
In this longitudinal, prospective study, we investi-
gated the occurrence and development of PHOMS and
optic disc drusen (ODD) in patients with MS and healthy
control subjects.8 We also studied how this novel observa-
tion related to non-MS disease controls and MS-specific
clinical data and integrity of the visual pathways on brain
magnetic resonance imaging (MRI).
Subjects and Methods
This prospective study was approved by the ethics com-
mittee of the Amsterdam University Medical Center (pro-
tocol number 2010/336) and the scientific research
committee (protocol number CWO/10-25D). The study
is in accordance with the Declaration of Helsinki. Written
informed consent was obtained from all subjects prior to
study inclusion.
Study Design and Patients
MS Disease Population. All subjects were recruited at the
Multiple Sclerosis Center at Amsterdam University Medi-
cal Center between March 2011 and August 2012.
Patients were assessed at baseline and after 2 years.
Inclusion criteria were a diagnosis of MS according
to the 2010 revision of the McDonald diagnostic criteria.9
Exclusion criteria were pregnancy, a relapse or a course of
steroids in the past 4 weeks, a diagnosis of human immu-
nodeficiency virus or other immunodeficiency, substance
abuse in the past 5 years, or MRI findings that could
interfere with evaluation. For healthy controls, additional
exclusion criteria were any other neurological, ophthalmo-
logical, or psychiatric disease or a first- or second-degree
relative with a diagnosis of MS. Episodes of MS optic
neuritis (MSON) were identified through patient history
and confirmed clinically using a standard care protocol.10
Subjects with ODD were excluded as per OSCAR-IB
criteria.11 At baseline screening, a total of 53 eyes were
excluded due to opacities in the visual pathways, abnormal
retinal or optic disc findings, or other problems.12 To be
consistent with previous publications on this cohort,12,13
the disease course was classified into relapsing–remitting,
secondary progressive, and primary progressive according
to the Lublin and Reingold classification.14
Non-MS Disease Control Population. The retrospective case
note review was approved by the Research and Develop-
ment Department of Moorfields Eye Hospital, London
(protocol number ROAD17/030). The diagnostic group-
ings were optic atrophy, isolated optic neuritis, referrals for
assessment of an incidentally detected anomalous optic disc,
increased intracranial hypertension (IIH), ODD, medical
retinal diseases, headaches, nonembolic transient visual field
loss, and those who experienced entoptic phenomena.
The retrospective control population was added after
the MS cohort study had finished. Therefore, only
descriptive statistics were performed to illustrate the gen-
eral distribution of PHOMS as may be encountered in
clinic.
OCT Protocol. All OCT images were obtained by spectral-
domain OCT (Heidelberg Spectralis; Heidelberg Engineer-
ing, Heidelberg, Germany; software v1.1.6.3) with eye-
tracking function enabled for best accuracy.15 Data were
collected from an optic disc volume scan (15 × 15, 37 B-
scans), peripapillary ring scan (12, 1 B-scan), and macular
volume scan (20 × 20, 49 B-scans). We could not
include enhanced depth imaging (EDI), because this feature
was added at a later stage to the software.
Automated segmentation was performed with the
manufacturer’s software (HEYEX v1.10.2.0, Viewing Mod-
ule v6.9.5.0). All scans underwent a rigorous quality control
check.11 Algorithm failures were corrected by hand. The
pRNFL, macular ganglion cell inner plexiform layer
(GCIPL), and macular inner nuclear layer thicknesses were
exported for statistical analysis. All OCT terminology used
follows consensus guideline recommendations.16 The ODD
consortium definition of PHOMS for OCT was used based
on consensus.5 We did not perform ultrasound.
MRI Protocol
Structural MRI was performed on a 3T whole body system
(SIGNA HDxt; GE Healthcare, Milwaukee, WI). The detailed
acquisition parameters have been described previously as well as
an example of the 3T MRI.12,13 In brief, normalized gray and
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white matter volumes and lesion volumes were quantified auto-
matically using k nearest neighbor classification with tissue type
priors, and SIENAX (part of FMRIB Software Library 5.0.4,
http://www.fmrib.ox.ac.uk/fsl). Lesion filling was applied to min-
imize the effect of lesions on atrophy measurements.
External Validation. External validation of the PHOMS
rating was performed (S.H.). The inter-rater agreement for
rating of PHOMS has been investigated using Fleiss kappa
statistics. The inter-rater kappa for the 2 independent raters
of PHOMS in the present study (A.P., S.H.) was 0.811 in
the multirater study of the ODD consortium.17
Statistical Analysis. The statistical analyses were per-
formed in SAS (v9.4). First, normality in measurements
was tested graphically and using Shapiro–Wilk statistics.
Nonparametric tests were used for non-normal or skewed
data and parametric tests for normally distributed data.
Median (interquartile range) or mean ± standard deviation
are shown. Differences between 2 groups were analyzed
using the chi-squared test for categorical variables, the
2-tailed t test for parametric continuous variables, and the
Mann–Whitney test for nonparametric continuous vari-
ables. General linear models were used for comparison of
data from >2 groups. Correlation analyses were performed
using Pearson r for normally distributed and Spearman
rho for non-Gaussian data. Bonferroni method was used
to correct for multiple correlations. Differences for seg-
mented retinal layer thickness data between groups was
analyzed using generalized estimation equations as rec-
ommended16; these were adjusted for intrasubject intereye
correlations and repeated measurements, and employed an
exchangeable correlation structure. Inter-rater agreement
on rating of PHOMS was assessed using Cohen kappa.
Missing data were handled as such and indicated in the
footnotes to the tables. A p value of 0.05 was accepted as
statistically significant.
Data Availability Statement
Anonymized data will be shared upon request from qualified
investigators.
Results
The baseline data of the 227 patients with MS and 62 con-
trol subjects are summarized in Table 1. Patients with MS
were only slightly older on average compared to the con-
trol subjects (p = 0.0105; 95% mean difference = 3.5 years,
95% confidence interval = 1 to 6 years).
Figure 1 shows the appearance of a normal optic disc
in comparison to an optic disc with PHOMS. The disc
shown in Figure 1B represents 1 of the 2 cases where
PHOMS did coexist with ODD. Because ODD were an
exclusion criterion, these 2 cases were excluded from all
further statistical analyses.
The inter-rater agreement for PHOMS was 97.9%,
with a kappa of 0.951. The proportion of PHOMS was
significantly higher in patients with MS (16%) when com-
pared to healthy control subjects (0%). Statistical signifi-
cance increased further for comparison of the proportion
of affected eyes (45 in MS and 0 in controls, p < 0.0001).
There was no significant age difference between patients
with MS who had PHOMS and those who did not
(p = 0.54). There was no association between presence of
PHOMS and the clinical disease course or disease dura-
tion (p = 0.26, p = 0.46, respectively).
Disease progression on the Expanded Disability Sta-
tus Scale (EDSS) was mild (Table 1). There was no statis-
tical relationship between progression on the EDSS and
presence or absence of PHOMS (p = 0.23).
Management with disease-modifying treatments
(DMTs) was not associated with presence of PHOMS
(chi-squared test, p = 0.83). Of the 4 patients with
fingolimod, only 1 had PHOMS.
The longitudinal images demonstrated 3 patterns of
PHOMS. First, PHOMS remained stable over the 2-year
observation period, as illustrated for a small PHOMS and
a larger PHOMS (Fig 2). Second, there was de novo
development of PHOMS. Finally, existing small PHOMS
could increase in size.
PHOMS and MSON
An episode of MSON had occurred in 144 eyes. The
location was on the right in 74 and on the left in 70 eyes.
Percentage of PHOMS in eyes affected by MSON was
10% on the right and 8% on the left. The percentage of
PHOMS in eyes never affected by MSON was 14% on
the right and 12% on the left. Overall, the presence of
PHOMS was not related to a history of MSON (chi-
squared test, p > 0.05). The patterns of PHOMS (stable,
de novo, increase) were not related to MSON.
PHOMS and Visual Pathway Integrity
Table 2 summarizes data on visual pathway integrity in
subjects with and without PHOMS.
In all eyes, there was progressive atrophy of the
pRNFL and GCIPL over the 2-year observation period.
At baseline, eyes from patients with PHOMS did have a
mildly thinner pRNFL and GCIPL if compared to
patients without PHOMS, but this did not reach statisti-
cal significance. Progression of atrophy was more marked
in eyes without PHOMS compared to eyes with PHOMS
for both layers, again without reaching statistical
significance.
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In patients without PHOMS, the fractional anisot-
ropy (FA) of the optic radiations was lower compared to
patients with PHOMS, and this appeared to be statisti-
cally significant (p = 0.0363). This difference was no lon-
ger statistically significant after Bonferroni correction for
multiple comparisons. Consistent with this finding, the
mean diffusivity was higher in the optic radiations of
patients with PHOMS compared to patients without
PHOMS, but this did not reach statistical significance.
Likewise, there was no statistically significant difference in
the degree of atrophy of the occipital cortex either for V1
or V2 comparing the 2 groups (Table 2).
The patterns of PHOMS (stable, de novo, increase)
were not related to these visual pathway data.
PHOMS in Non-MS Disease Controls
An additional retrospective case note review was per-
formed on 267 patients who had for their routine clinical
workup OCT optic nerve head volume imaging. Table 3
summarizes the subject characteristics for the disease
groups. Overall, PHOMS were more frequent than
ODD. Conditions associated most frequently with
PHOMS were IIH (62%), ODD (47%), and anomalous
optic discs (44%). The percentage of PHOMS in patients
with an isolated optic neuritis (19%) and optic atrophy
(12%) was comparable to the patients with MSON (18%
of MSON eyes; see above).
Discussion
There are 4 main findings from this study. First, PHOMS
can clearly be seen in patients with MS using a routine
optic nerve head OCT volume scan, with an excellent
inter-rater kappa of 0.951. Second, PHOMS are signifi-
cantly more frequently present in patients with MS com-
pared to healthy controls. Third, in patients with
PHOMS, the optic radiations have a significantly higher
FA compared to patients without PHOMS. Both findings
are relevant because they provide indirect evidence for
impaired axoplasmic flow in the visual pathways of
patients with MS (Fig 3). Finally, there are 3 types of
TABLE 1. Subject Characteristics
Controls Patients p
Subjects 62 227
Eyes 117 418
Gender, F:M 41:21 155:72 ns
Age, yr 50.6 (7.1) 54.1 (10.0) 0.01a
Disease duration, yr n/a 20.4 (6.9)
Follow-up, mo 27.5 (2.9) 26.0 (2.7) ns
EDSS n/a 4.2 (1.7)
EDSS progression n/a 0.3 (0.7)
Disease course n/a 139 RR, 28 PP, 60 SP
MSON None 32 right, 30 left, 39 bilateral, 126 never
DMT n/a IFN, 65; FTY, 4; AZT, 1; MTX, 3; 1,
ATM-027; NTZ, 10; GA, 15; teriflunomide, 1
ODD 1 (2%) 1 (1%) ns
PHOMS 0 (0%) 34 (16%) all MS, 21 (16%) RR, 6 (12%) SP, 7 (16%) PP <0.001b
Mean (standard deviation) or n (%) is shown.
aThe Bonferroni adjusted p value for multiple comparisons (n = 5) is 0.01.
bThe statistical significance of this finding increases to p < 0.0001 if the number of eyes (45/373 vs 0/117) instead of the number of patients (as shown
in the table) is taken for comparison.
AZT = azathioprine; DMT = disease-modifying treatment; EDSS = Expanded Disability Status Scale; F = female; FTY = fingolimod; GA = glatiramer
acetate; IFN = interferon beta 1a and 1b; M = male; MS = multiple sclerosis; MSON = multiple sclerosis optic neuritis; MTX = mitoxantrone; n/a =
not applicable; ns = not significant; NTZ = natalizumab; ODD = optic disc drusen; PHOMS = peripapillary hyper-reflective ovoid masslike structure;
PP = primary progressive; RR = relapsing–remitting; SP = secondary progressive.
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PHOMS: (1) PHOMS that remain stable, (2) PHOMS
that increase in size, and (3) PHOMS that develop
de novo.
It is important to note that presence of PHOMS is
an observation independent of biases by key clinical fea-
tures. This makes PHOMS an interesting new object to
study and a hitherto unknown aspect of pathology in
MS. Specifically, it has been excluded that PHOMS were
observed more frequently in patients with MSON as com-
pared to those who never experienced MSON.10 This
observation was confirmed in the non-MS cohort for iso-
lated optic neuritis. This is relevant because PHOMS can
be observed in the course of a whole range of etiology
leading to optic disc swelling (personal observation, A.P.).
Next, PHOMS were not related to the degree of either
pRNFL or GCIPL atrophy. Neither were degree of atro-
phy of the pRNFL or GCIPL associated with PHOMS.
Longitudinally, PHOMS, even if developing, were not
related to progression of atrophy. Again, the finding was
confirmed by the data from the non-MS cohort for optic
atrophy. This is an observation that, for example, can be
made with ODD causing progressive visual field defects.18
The known association between more severe retinal inner
layer atrophy and progression of disability on the EDSS19
cannot be shown for PHOMS. There was no relationship
between PHOMS and use of DMTs. This is relevant
because, for example, fingolimod has been identified as a
cause for macular edema.20 Likewise, there was no associa-
tion of PHOMS with demographic data or disease dura-
tion. The latter can, however, also be interpreted as a
limitation of the study, because we cannot comment on
PHOMS during the early disease course of MS. Patients
in this study had a long disease duration of about
20 years. A strength of the study is, however, the longitu-
dinal data, with an averaged follow-up period of 26 to
27 months.
After having ruled out an association of PHOMS
with demographic or clinical data, it is possible to return
to the observation with an unbiased mind. In MS, there
are very few patients with PHOMS, and in these patients,
one can observe a significant increase of the FA in the
optic radiations. Anatomically, the first observation locates
to the anterior and the second to the posterior optic path-
ways. What could be an explanation connecting the two?
There are at least 3 potential explanations to discuss:
(1) axoplasmic stasis and localized aggregate formation,
(2) the glymphatic system, and (3) the translaminar pres-
sure gradient at the optic disc.
FIGURE 1: (A): A normal optic disc. (B) An optic disc with peripapillary hyper-reflective ovoid masslike structures (PHOMS) and
optic disc drusen (ODD). The hyperintense PHOMS typically transverse several of the retinal layers, in this case from the retinal
nerve fiber layer down to the basal membrane. The ODD are located above and below Bruch’s membrane and impress as
conglomerates of low-intensity signal with intermingled hyperintense small horizontal lines. This appearance is very different
from the vertical shadow cast by blood vessel artifacts. The confocal laser scanning ophthalmoscopy is shown on the left. The
green lines indicate the location of the optical coherence tomographic B-scan shown on the right. [Color figure can be viewed at
www.annalsofneurology.org]
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The first argument builds on an earlier indirect
observation of impaired axonal transport and aggregated
formation.21 In MS, some axons, particularly those adja-
cent to MS lesions, show signs of increased neurofilament
compactness and aggregation in the axolemma. Neuro-
filaments are a key component of the axonal cytoskele-
ton.22,23 Therefore, the observation of axonal swellings
indicating a reversible form of axonal damage is intrigu-
ing.24 The images shown in this elegant study demon-
strate local accumulation of neurofilament proteins in
axonal swelling.24 Could PHOMS be a late sign for
reversible axonal damage in MS? Future immunohisto-
chemical postmortem studies of PHOMS in the retina of
patients with MS will be needed to clarify whether neu-
rofilament proteins or myelin products can be found in
PHOMS. Such future studies should also investigate the
role of phosphorylation of neurofilaments and other
proteins, which significantly affect MRI metrics.25 One
question arising from the observation of the increased FA
is whether proton mobility in the optic pathways (see
Fig 3A) of patients with PHOMS is influenced by accu-
mulation, aggregation, and phosphorylation of proteins,
all contributing to impaired axonal flow. This line of argu-
mentation may be useful for helping to explain the other-
wise paradoxical observation of an increase of the RNFL
over time in some patients with MS and in experimental
models.26,27
The second hypothesis builds on the observation of
impairment of the glymphatic system.28 Hamann et al
have demonstrated that water channel (aquaporin) distri-
bution in the eye provides an excellent anatomical basis
for a presumed ocular glymphatic system.29,30 Therefore,
it could be possible that an impaired glymphatic system
through aquaporins in MS reduces the ability to remove
FIGURE 2: Examples of peripapillary hyper-reflective ovoid masslike structures (PHOMS) in patients with multiple sclerosis. (A) A
small PHOMS that remained stable in size over the 2-year observation period. The baseline image is shown on the top (red
frame) and the follow-up image on the bottom. (B) A larger PHOMS that also remained stable over time. (C) A de novo PHOMS
that developed. (D) A small PHOMS at baseline that has increased in size over 2 years. The confocal laser scanning
ophthalmoscopy is shown on the left. The green lines indicate the location of the optical coherence tomographic B-scan shown
on the right. [Color figure can be viewed at www.annalsofneurology.org]
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TABLE 2. PHOMS and Visual Pathway Integrity in Multiple Sclerosis
PHOMS− PHOMS+ p
Eyesa
n 427 40
pRNFL baseline, μm 86.34 ± 13.91 84.83 ± 12.96 ns
pRNFL follow–up, μm 84.03 ± 14.44 84.57 ± 12.48 ns
Δ pRNFL, μm −0.77 ± 1.98 −0.09 ± 2.22 ns
GCIPL baseline, μm 80.07 ± 14.58 79.53 ± 13.49 ns
GCIPL follow–up, μm 78.64 ± 14.92 78.06 ± 13.49 ns
Δ GCIPL, μm −0.65 ± 1.51 −0.15 ± 1.19 ns
Patientsb
n 173 33
Optic radiations
MD 1.905 ± 0.197 1.863 ± 0.169 ns
FA 0.814 ± 0.084 0.845 ± 0.073 0.03c
Visual cortex
V1 3.56 ± 0.25 3.52 ± 0.21 ns
V2 4.10 ± 0.23 4.06 ± 0.23 ns
aThere were n = 5 eyes of patients with PHOMS and n = 33 eyes of patients without PHOMS who failed quality control for quantitative data for
either the pRNFL or GCIPL.
bThe magnetic resonance imaging metrics were not available from 1 patient with PHOMS and n = 49 patients without PHOMS.
cThe Bonferroni-adjusted p value for multiple comparisons (n = 4) is 0.0125.
FA = fractional anisotropy; GCIPL = ganglion cell inner plexiform layer; MD = mean diffusivity; ns = not significant; PHOMS = peripapillary hyper-
reflective ovoid masslike structure; pRNFL = peripapillary retinal nerve fiber layer.
TABLE 3. Subject Characteristics of the Retrospective Non–Multiple Sclerosis Disease Control Cohort (n = 267)
ION OA Disc Cog Opt Pain IIH MR ODD TMVL
Subjects 16 49 81 4 17 19 13 20 38 10
Eyes 32 98 162 8 34 38 26 40 76 20
Gender, F:M 10:6 22:27 53:28 2:2 12:5 15:4 12:1 9:11 21:17 6:4
Age, yr 44.5
(19.1)
53.2
(16.6)
34.0
(14.4)
40.8
(7.7)
38.4
(11.9)
36.0
(13.1)
29.7
(9.2)
44.7
(18.4)
38.4
(15.7)
43.5
(15.1)
ODD 1 (6%) 3 (6%) 6 (7%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 38 (100%) 0 (0%)
PHOMS 3 (19%) 6 (12%) 36 (44%) 1 (1%) 0 (0%) 3 (16%) 8 (62%) 1 (1%) 18 (47%) 1 (10%)
Mean (SD) or n (%) is shown.
Cog = cognitive; Disc = anomalous discs; F = female; IIH = increased intracranial hypertension; ION = isolated optic neuritis; M = male; MR = medi-
cal retinal disease; OA = optic atrophy; ODD = isolated optic disc drusen; Opt = entoptic phenomena; Pain = headaches not due to IIH; PHOMS =
peripapillary hyper-reflective ovoid masslike structure; TMVL = nonembolic transient monocular visual field loss.
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extracellular waste products such as compounds extrava-
sated during axoplasmic stasis (see Fig 3C).31 There have
been independent lines of argumentation in the past
5 years raising the likelihood of such a retinal glymphatic
system.32–35 The longitudinal data from this study show
that the increase of size of PHOMS had been very mild
over a 2-year period. Such a slow dynamic would be more
consistent with a glymphatic problem, rather than being a
consequence of more acute pathology, particularly after rel-
evant demographic and clinical factors have been ruled out.
The third hypothesis is related to the second and offers
a mechanistic approach to the previous two. The translaminar
pressure gradient at the optic disc (see Fig 3B) has been
suggested as a relevant factor in driving neurodegeneration in
a chronic optic neuropathy, glaucoma.36 We are not aware of
data on PHOMS in the glaucoma literature, but another
example of transient change of the translaminar pressure gra-
dient at the optic disc is IIH. The development of PHOMS
in patients with IIH has been observed, as well as PHOMS
regression after treatment37 (personal observation, A.P.).
Recent reports on an elevated lumbar opening pressure in
MS come from the pediatric literature.38,39 However, the
observation had been made reliably by experienced neuro-
ophthalmologists anecdotally in adults.40 All of their 3 patients
reported headaches, and lumbar puncture opening cerebrospi-
nal fluid pressures were >29cm H2O, 42cm H2O, and 25cm
H2O.
40 Contemporary routine examination of the cerebrospi-
nal fluid in patients with MS does not include measurement
of the opening pressure.41 Future studies investigating the
hypothesis that there could be intermittent intracranial pres-
sure elevation in MS (see Fig 3B) are advised to follow a
well-designed protocol for calibrated pressure measurements
of the eye and brain.42 This will be of particular interest in
patients in whom PHOMS develop de novo or increase in
size over time. These observations provide indirect evidence
for a glymphatic system that connects the eye with the brain.
Above interpretations of our data also highlight the
most relevant shortcomings. There are no recent histologi-
cal data showing PHOMS in MS that shed light on the
underlying pathology. The published immunohistochemi-
cal images of postmortem optic discs in MS by Green
et al show degrees of axonal atrophy, but these samples
did not contain eyes from patients with PHOMS.43 Argu-
ably, the 3 cases presented historically by Norris did not
present optic neuritis as defined by von Graefe and
Nettleship.1,2 Instead, he described optic disc edema in
the context of other pathology.3 Nevertheless, these
authors reported an important histological observation
that, given the alternative pathology and the findings in
our non-MS cohort, remind us that PHOMS are not spe-
cific to MS. Similar to what has been reported for other
new OCT-based observations in MS, PHOMS can be
found with a whole range of clinical pathologies, and in a
clinical context are most frequently misinterpreted as
pseudopapilledema (personal observation, A.P.).
FIGURE 3: Development of peripapillary hyper-reflective ovoid
masslike structures (PHOMS) in multiple sclerosis. (A) The
anatomy of the visual pathways in relation to the brain and
cerebrospinal fluid (CSF) spaces. Increased intracranial pressure
(ICP) and aggregate formation in the optic pathwaysmay result in
development of PHOMS (arrows). (B) PHOMS are located in the
peripapillary area, where they are in close anatomical proximity
to axons leaving the eye to form the optic nerve, the CSF in the
optic nerve sheet, the central retinal artery (CRA), and the central
retinal vein (CRV). A change of the translaminar pressure gradient
(before/after lamina cribrosa) may result in axoplasmic stasis and
reduced glymphatic outflow (arrows), resulting in PHOMS.
(C) PHOMS have a local mass effect that typically displaces
content from several retinal layers. This can give the impression of
pseudopapilledema. Axoplasmic stasis and impaired glymphatic
outflow through the perivascular space of the optic nerve may
contribute to buildup of PHOMS (arrows). GCL = ganglion cell
layer; INL = inner nuclear layer; IPL = inner plexiform layer;
LGN = lateral geniculate ganglion; ONL = outer nuclear layer;
OPL = outer plexiform layer; RNFL = retinal nerve fiber layer;
RPE= retinal pigment epithelium.
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Technical limitations of the study are related to soft-
ware updates. Very small ODD below Bruch’s membrane
can escape detection without use of EDI. The ODD con-
sortium has therefore developed a highly sensitive ODD
imaging protocol that should be employed in future stud-
ies on PHOMS in MS (see Table 1 in Malmqvist et al5).
Likewise, we did not quantitatively assess the relative affer-
ent pupillary defect, which would be an interesting addi-
tional metric for visual function to be correlated to
PHOMS.44,45
Clinical limitations of the study are related to the
retrospective nature of the non-MS cohort. The retrospec-
tive cohort does, however, permit examining in more gen-
eral terms the association of PHOMS with other diseases.
This is clinically relevant because of the differential diag-
nosis of IIH. If PHOMS are misinterpreted clinically as
true disc swelling, then there is a risk of overestimating
IIH. In 16% of cases with a primary headache disorder,
the presence of PHOMS will give the impression of
pseudopapilledema. The difficulty interpreting PHOMS
as a cause for pseudopapilledema is also reflected in the
high referral pattern to clinics of patients with what has
been classified as an “anomalous disc.” In 44%, this was
due to PHOMS. The presence of PHOMS in 19% of
patients with an isolated optic neuropathy and 12% of
patients with optic atrophy will require future research.
For example, the ODD Consortium has identified
PHOMS as a novel, independent risk factor for young
onset (<50 years), nonarteritic ischemic optic neuropathy.
Likewise, almost half of all patients with ODD also harbor
PHOMS. Taken together, the clinical limitations of the
post hoc retrospective addition of the non-MS cohort does
still add valuable clinical information.
It is worthwhile to reflect on the study limitations in
a broader context. To date, work on the glymphatic sys-
tem largely relies on histological data from tracer studies
in rodents.46,47 There is a need for other methodological
approaches suitable for longitudinal in vivo human stud-
ies. This is required to study any presumed relationships
to disease processes. The hypothesis to be investigated fur-
ther in MS research is whether impairment of the
glymphatic system could contribute to explaining reduced
clearance of potentially immunogenic compounds from
the paravascular space. Approaches in this direction are
needed to explain the pathognomonic but enigmatic peri-
vascular compartmentalization of lymphocytes in the brain
of patients with MS.48 A further limitation is that the only
MRI parameter we found to be associated with presence
of PHOMS, FA, does not have pathological specificity.
Lower FA is typically thought to represent bundle atro-
phy. FA can increase as a result of restricted perpendicular
diffusivity, facilitated parallel diffusivity, or some
combination of the two. Future studies may benefit from
advanced multimodal brain imaging, including positron
emission tomography with novel dynamic tracers.49 Other
limitations of our study relate to the regular update of
consensus criteria. For internal consistency with our previ-
ous publications,12,13 we adhered to the 2010 revision of
the McDonald criteria and the 1996 Lublins classification.
All of our patients also met the 2017 revision of the
McDonald criteria.41 However, there have been relevant
changes to the disease course in the revision to the disease
course.50 The main difference relates to "active" and "non-
active" disease. In this context, observed development of
PHOMS over time may be interrogated as an alternative
approach to recognize disease activity that may be of inter-
est for future revisions of such classifications. Probably the
most relevant limitation comes, however, from a recent
debate.51–54 The existence of a glymphatic transport sys-
tem from the eye to the brain has just been demonstrated
experimentally in rodents.55
In conclusion, this study shows that a small pro-
portion of patients with MS harbor PHOMS. In these
patients, PHOMS can slowly increase in size over time
or develop de novo. There are plausible mechanisms that
can explain this development. The presence of PHOMS
may be caused by axoplasmic stasis, impairment of a
presumed glymphatic system from the eye through the
optic nerve, or change of the translaminar pressure gra-
dient at the optic disc. Taken together, PHOMS are a
novel finding in MS that might be useful for study of a
hitherto unexplored pathway in MS, the glymphatic
system.
Acknowledgment
A.P. and P.A.K. are supported by the National Institute
for Health Research (NIHR) Biomedical Research Centre
based at Moorfields Eye Hospital National Health Service
(NHS) Foundation Trust and University College London
Institute of Ophthalmology. The views expressed are those
of the authors and not necessarily those of the NHS, the
NIHR, or the Department of Health.
We are grateful for the chairs’ and audience com-
ments on the data, which were presented to the European
Committee for Treatment and Research in Multiple Scle-
rosis in Berlin.8
Author Contributions
A.P., B.M.J.U., and L.J.B. contributed to the conception
and design of the study; A.P., D.C., D.P.C., L.J.B., A.K.D.,
P.A.K and S.H. contributed to the acquisition and analysis
of data; A.P. drafted the text and prepared the figures.
9
Petzold et al: PHOMS in MS
Potential Conflicts of Interest
A.P. is part of the steering committee of the ANGI net-
work, which is sponsored by Zeiss, and steering commit-
tee of the OCTiMS study, which is sponsored by
Novartis and reports speaker fees from Heidelberg Engi-
neering. P.A.K. reports speaker fees from Zeiss, Topcon,
Heidelberg Engineering, and Haag-Streit and has received
consultancy fees from DeepMind and Optos. The other
authors have nothing to report.
References
1. von Graefe A. Über Complication von Sehnervenentzündung mit
Gehirnkrankheiten. Arch Ophthalmol 1860;1:58–71.
2. Nettleship E. On cases of retro-ocular neuritis. Trans Ophthalmol Soc
UK 1884;4:186–226.
3. Norris W. Cases of optic neuritis. Trans Am Ophthalmol Soc 1874;2:
162–169.
4. Petzold A, de Boer JF, Schippling S, et al. Optical coherence tomog-
raphy in multiple sclerosis: a systematic review and meta-analysis.
Lancet Neurol 2010;9:921–932.
5. Malmqvist L, Bursztyn L, Costello F, et al. The optic disc drusen stud-
ies consortium recommendations for diagnosis of optic disc drusen
using optical coherence tomography. J Neuroophthalmol 2017;38:
299–307.
6. Malmqvist L, Bursztyn L, Costello F, et al. Peripapillary hyper-
reflective ovoid mass-like structures: is it optic disc drusen or not?:
response. J Neuroophthalmol 2018;38:568–570.
7. Petzold A, Balcer LJ, Calabresi PA, et al. Retinal layer segmentation
in multiple sclerosis: a systematic review and meta-analysis. Lancet
Neurol 2017;16:797–812.
8. Petzold A, Coric D, Uitdehaag BM, Balk L. Peripapillary hyper-
reflective ovoid mass-like structures in multiple sclerosis are associ-
ated with disease progression. ECTRIMS Online Library 2. 2018;18:
232046. https://onlinelibrary.ectrims-congress.eu/ectrims/2018/
ectrims-2018/232046/axel.petzold.peripapillary.hyperreflective.
ovoid.mass-like.structures.in.html.
9. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for
multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neu-
rol 2011;69:292–302.
10. Petzold A, Wattjes MP, Costello F, et al. The investigation of acute
optic neuritis: a review and proposed protocol. Nat Rev Neurol
2014;10:447–458.
11. Tewarie P, Balk L, Costello F, et al. The OSCAR-IB consensus criteria
for retinal OCT quality assessment. PLoS One 2012;7:e34823.
12. Balk LJ, Twisk JWR, Steenwijk MD, et al. A dam for retrograde axo-
nal degeneration in multiple sclerosis? J Neurol Neurosurg Psychia-
try 2014;85:782–789.
13. Balk LJ, Steenwijk MD, Tewarie P, et al. Bidirectional trans-synaptic
axonal degeneration in the visual pathway in multiple sclerosis.
J Neurol Neurosurg Psychiatry 2015;86:419–424.
14. Lublin F, Reingold S, National Multiple Sclerosis Society (USA) Advi-
sory Committee on Clinical Trials of New Agents in Multiple Sclero-
sis. Defining the clinical course of multiple sclerosis: results of an
international survey. Neurology 1996;46:907–911.
15. Balk LJ, Petzold A. Influence of the eye-tracking-based follow-up
function in retinal nerve fiber layer thickness using Fourier-domain
optical coherence tomography. Invest Ophthalmol Vis Sci 2013;54:
3045.
16. Cruz-Herranz A, Balk LJ, Oberwahrenbrock T, et al. The APOSTEL
recommendations for reporting quantitative optical coherence
tomography studies. Neurology 2016;86:2303–2309.
17. Petzold A, Biousse V, Bursztyn L, et al. Multirater validation of peri-
papillary hyperreflective ovoid mass-like structures (PHOMS). Neuro-
ophthalmology in press. https://doi.org/10.1080/01658107.2020.
1760891.
18. Malmqvist L, Kyhnel A, Hamann S. Substantial visual field loss associ-
ated with giant optic disc drusen. JAMA Ophthalmol 2017;135:
e174778.
19. Martinez-Lapiscina EH, Arnow S, Wilson JA, et al. Retinal thickness
measured with optical coherence tomography and risk of disability
worsening in multiple sclerosis: a cohort study. Lancet Neurol 2016;
15:574–584.
20. Afshar AR, Fernandes JK, Patel RD, et al. Cystoid macular edema
associated with fingolimod use for multiple sclerosis. JAMA
Ophthalmol 2013;131:103–107.
21. Petzold A, Gveric D, Groves M, et al. Phosphorylation and compact-
ness of neurofilaments in multiple sclerosis: indicators of axonal
pathology. Exp Neurol 2008;213:326–335.
22. Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers
in neurological disorders. Nat Rev Neurol 2018;14:577–589.
23. Petzold A. Neurofilament phosphoforms: surrogate markers for axo-
nal injury, degeneration and loss. J Neurol Sci 2005;233:183–198.
24. Nikic I, Merkler D, Sorbara C, et al. A reversible form of axon dam-
age in experimental autoimmune encephalomyelitis and multiple
sclerosis. Nat Med 2011;17:495–499.
25. Petzold A, Tozer D, Schmierer K. Axonal damage in the making: neu-
rofilament phosphorylation, proton mobility and magnetisation trans-
fer in multiple sclerosis normal appearing white matter. Exp Neurol
2011;232:234–239.
26. Serbecic N, Aboul-Enein F, Beutelspacher SC, et al. Heterogeneous
pattern of retinal nerve fiber layer in multiple sclerosis. High resolu-
tion optical coherence tomography: potential and limitations. PLoS
One 2010;5:e13877.
27. Manogaran P, Samardzija M, Schad AN, et al. Retinal pathology in
experimental optic neuritis is characterized by retrograde degenera-
tion and gliosis. Acta Neuropathol Commun 2019;7:116.
28. Lenck S, Radovanovic I, Nicholson P, et al. Idiopathic intracranial
hypertension: the veno glymphatic connections. Neurology 2018;91:
515–522.
29. Hamann S, Zeuthen T, La Cour M, et al. Aquaporins in complex tis-
sues: distribution of aquaporins 1-5 in human and rat eye.
Am J Physiol 1998;274:C1332–C1345.
30. Hamann S. Molecular mechanisms of water transport in the eye. Int
Rev Cytol 2002;215:395–431.
31. Brenner SR. Brain glymphatic system may be impaired in MS. Neu-
rology 2013;80. https://n.neurology.org/content/brain-glymphatic-
system-may-be-impaired-ms.
32. Denniston AK, Keane PA. Paravascular pathways in the eye: is there
an ocular glymphatic system. Invest Ophthalmol Vis Sci 2015;56:
3955–3956.
33. Petzold A. Retinal glymphatic system: an explanation for transient
retinal layer volume changes? Brain 2016;139:2816–2819.
34. Wostyn P, De Groot V, Van Dam D, et al. Age-related macular
degeneration, glaucoma and Alzheimer’s disease: amyloidogenic
diseases with the same glymphatic background? Cell Mol Life Sci
2016;73:4299–4301.
35. Spaide RF. Retinal vascular cystoid macular edema: review and new
theory. Retina 2016;36:1823–1842.
36. Jonas JB, Ritch R, Panda-Jonas S. Cerebrospinal fluid pressure in the
pathogenesis of glaucoma. Prog Brain Res 2015;221:33–47.
10 Volume 00, No. 0
ANNALS of Neurology
37. Malmqvist L, Sibony PA, Fraser CL, et al. Peripapillary ovoid hyper-
reflectivity in optic disc edema and pseudopapilledema. Ophthal-
mology 2018;125:1662–1664.
38. Narula S, Liu GT, Avery RA, et al. Elevated cerebrospinal fluid open-
ing pressure in a pediatric demyelinating disease cohort. Pediatr
Neurol 2015;52:446–449.
39. Williams BJ, Skinner HJ, Maria BL. Increased intracranial pressure in a
case of pediatric multiple sclerosis. J Child Neurol 2007;23:699–702.
40. Newman NJ, Selzer KA, Bell RA. Association of multiple sclerosis
and intracranial hypertension. J Neuroophthalmol 1994;14:189–192.
41. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple
sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol
2018;17:162–173.
42. Eklund A, Jóhannesson G, Johansson E, et al. The pressure differ-
ence between eye and brain changes with posture. Ann Neurol
2016;80:269–276.
43. Green AJ, McQuaid S, Hauser SL, et al. Ocular pathology in multiple
sclerosis: retinal atrophy and inflammation irrespective of disease
duration. Brain 2010;133:1591–1601.
44. Meneguette NS, de Carvalho JER, Petzold A. A 30 s test for quanti-
tative assessment of a relative afferent pupillary defect (RAPD): the
infrared pupillary asymmetry (IPA). J Neurol 2019;266:969–974.
45. Schmidt FA, Connolly F, Maas MB, et al. Objective assessment of a
relative afferent pupillary defect by B-mode ultrasound. PLoS One
2018;13:e0202774.
46. Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from
the adult brain. Science 2013;342:373–377.
47. Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF
flow through the brain parenchyma and the clearance of interstitial
solutes, including amyloid. Science Transl Med 2012;4(147):147ra111–
147ra111. http://dx.doi.org/10.1126/scitranslmed.3003748.
48. Machado-Santos J, Saji E, Tröscher AR, et al. The compartmentalized
inflammatory response in the multiple sclerosis brain is composed of
tissue-resident CD8 T lymphocytes and B cells. Brain 2018;141:
2066–2082.
49. Schubert JJ, Veronese M, Marchitelli L, et al. Dynamic 11C-PiB PET
shows cerebrospinal fluid flow alterations in Alzheimer’s disease and
multiple sclerosis. J Nucl Med 2019;60:1452–1460.
50. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course
of multiple sclerosis: the 2013 revisions. Neurology 2014;83:
278–286.
51. De Simone R, Ranieri A. Reader response: Idiopathic intracranial
hypertension: the veno glymphatic connections. Neurology 2019;
93:43.
52. Ganesh A, Galetta S. Editors’ note: Idiopathic intracranial hyperten-
sion: the veno glymphatic connections. Neurology 2019;93:42.
53. Kronenberg G, Kunte H. Reader response: Idiopathic intracranial
hypertension: the veno glymphatic connections. Neurology 2019;93:
43–44.
54. Lenck S, Nicholson P. Author response: Idiopathic intracranial hyper-
tension: the veno glymphatic connections. Neurology 2019;93:
44–45.
55. Wang X, Lou N, Eberhardt A, et al. An ocular glymphatic clearance
system removes β-amyloid from the rodent eye. Sci Transl Med
2020;12:eaaw3210.
11
Petzold et al: PHOMS in MS
